Search Results

Indiana University Health Establishes Center of Excellence in Theranostics to Advance Precision Targeted Cancer Therapy

Indiana University Health is establishing a new Center of Excellence in Theranostics, planning to provide cancer patients with more personalized diagnostic and treatment services through theranostic technologies. The project combines advanced medical imaging, precision diagnostics, and image-guided targeted therapy, aiming to enhance access to relevant medical services for patients in Indiana. Partial funding comes from a $20 million donor contribution, with Indiana University providing matching funds to bring total donations to $40 million. According to Indiana University, theranostics is a technological approach that integrates diagnosis and treatment. Clinically, advanced imaging techniques are first used...

2026-08-23

Global PET Market Expected to Reach $2.81 Billion by 2035, PET-CT Remains Dominant

A market research report shows that the global Positron Emission Tomography (PET) market size is expected to increase from $1.86 billion in 2025 to $2.81 billion by 2035, with a compound annual growth rate (CAGR) of 4.26% from 2026 to 2035. Increased demand for cancer diagnosis, expanded application of hybrid imaging technologies such as PET-CT and PET-MRI, and continued development of molecular imaging technologies are considered major factors driving market growth. The report notes that PET scans are being increasingly used in scenarios such as cancer detection and treatment evaluation, cardiac disease assessment, and diagnosis of neurological and psychiatric disorders. Meanwhile, population aging, rising healthcare expenditures, and growing demand for early screening are also driving...

2026-08-23

Construction of Radiotherapy and Radiosurgery Center Completed at Bulgaria's St. Ivan Rilski University Hospital

All construction and repair work for the new Radiotherapy and Radiosurgery Center at Bulgaria's St. Ivan Rilski University Hospital has been fully completed. According to the hospital, a latest-generation medical linear accelerator has been installed in the center, capable of sub-millimeter patient positioning accuracy. The equipment was delivered by the Ministry of Health under the National Recovery and Resilience Plan, as part of the investment project for the modernization of the national system for diagnosis and treatment of oncological diseases, funded by the European Commission's Recovery and Resilience Facility. The device is a TrueBeam-EDGE linear accelerator manufactured by Varian Medical Systems, equipped with BrainLab's ExactTrac Dynamic system, valued at 5.1 million...

2026-08-21

Five New Oncology Diagnostic and Treatment Devices at Bulgaria's ISUL Hospital Expected to Launch This Autumn

Queen Joanna - ISUL University Hospital in Bulgaria expects to begin operating five new devices for imaging diagnosis and treatment of oncological diseases starting early this autumn. The hospital stated that patients will be able to use these high-tech devices after the relevant licensing and approval procedures are completed. Source: Queen Joanna University Hospital - ISULThe newly added equipment is deployed in the imaging diagnostics department and the radiation oncology department. Among them, the radiation therapy department will be equipped with a TrueBeam v4.1 medical linear accelerator, primarily used for radiotherapy and radiosurgery. This device can deliver high-energy radiation to tumor tissue with greater precision, supporting high-precision dose planning to achieve the required therapeutic effect while minimizing radiation exposure to healthy tissues and organs surrounding the tumor.

2026-08-21

South Korea's National Assembly Passes Amendments on Radiation Disaster Response, Strengthening the Treatment System for Radiation Victims

The South Korean National Assembly held a plenary session on the 20th and passed two livelihood bills proposed by Rep. Yoon Jun-byeong, a member of the Parliamentary Agriculture, Food, Rural Affairs and Fisheries Committee. The bills concern the establishment of a radiation disaster response system and adjustments to the support system for surviving family members of national meritorious persons. Under the amendments passed, the Korea Atomic Energy Research Institute will be granted the qualification to operate as a specialized hospital for treating radiation victims. This arrangement aims to further improve the national medical safety net, enabling industrial radiation workers and victims of accidental radiation incidents to receive faster and more systematic treatment and rehabilitation support. Meanwhile, another amendment was also passed. This amendment, in accordance with the Constitutional Court's ruling of nonconformity, abolishes the provision that prioritized age as the sole criterion in the payment of survivor benefits to families of national meritorious persons of the same rank. After the relevant institutional adjustment, greater emphasis will be placed on safeguarding the rights of low-income households to reduce blind spots in welfare support.

2026-08-21

Iran Restarts Cyclotron to Boost Supply of Radiopharmaceuticals for Cancer Diagnosis and Treatment

Iranian nuclear industry experts have recently resumed operation of a cyclotron used in nuclear medicine, which can produce radioisotopes needed for cancer diagnosis and treatment. According to plans, by the end of Iran's Seventh Development Plan, i.e., March 2029, Iran will have seven such centers to expand domestic supply capacity for medical radioisotopes. A cyclotron is a type of particle accelerator that can be used to produce nuclear medicine radioisotopes and further prepare radiopharmaceuticals. These drugs can be used for the detection, diagnosis, and monitoring of malignant tumors. Data shows that related products produced domestically in Iran include FDG and F-PSMA, primarily serving nuclear medicine diagnosis and treatment for various cancers...

2026-08-21

Norroy Bioscience's 68Ga-NYM096 Receives FDA Breakthrough Therapy and Fast Track Designations

China-based Norroy Bioscience announced on August 19 that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy and Fast Track designations to its radiopharmaceutical imaging agent 68Ga-NYM096. The agent is a PET imaging tracer targeting carbonic anhydrase IX (CAIX), intended for imaging clear cell renal cell carcinoma (ccRCC). According to the company, 68Ga-NYM096 is being developed as a non-invasive PET imaging tool to characterize renal masses detected by CT or MRI and to help distinguish clear cell renal cell carcinoma from other non-ccRCC renal lesions. Clear cell renal cell carcinoma is the most common subtype of renal cell carcinoma...

2026-08-21

Atom High-Tech and CNNC Headway Visit Tsinghua University for Business Cooperation Exchange

On August 17, Luo Xu, General Manager of Atom High-Tech, and Liu Wen, Chairman of CNNC Headway, led a delegation to Tsinghua University for a business cooperation exchange with the School of Biomedical Engineering. Hu Ye, Dean of the School of Biomedical Engineering, and Ma Kai, Associate Professor of the School, attended the exchange. The visit aimed to leverage the research and talent advantages of a top-tier university, promote deep integration of industry, academia, and research, and jointly explore new cooperation opportunities in the fields of nuclear medicine and biomedical engineering. During the exchange meeting, Atom High-Tech and CNNC Headway respectively introduced their corporate development histories, core business layouts, and future strategic plans. Subsequently, Dean Hu Ye and Associate Professor Ma Kai respectively introduced...

2026-08-21

Brazilian CancerThera Delegation Visits Uruguay's CUDIM to Advance Theranostics Cooperation in Oncology

Following the institutional partnership established between CEPID CancerThera and the Uruguayan Center for Molecular Imaging (CUDIM) in February this year, a Brazilian delegation visited Montevideo, Uruguay, from July 27 to 29 to advance the transformation of the memorandum of understanding into a concrete work plan. The visit focused on multicenter clinical trials, preclinical research, theranostics in oncology, and educational cooperation. During the visit, Brazilian researchers held working meetings with the CUDIM team, covering multiple aspects of oncology research development. CUDIM was represented by its General Director Alarico Rodriguez, as well as radiopharmacist and Technical Director of Radiopharmacy, Dr. Eduardo Osvaldo Savio Queve...

2026-08-20

Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Radiopharmaceutical Development for Solid Tumors

Akiram Therapeutics, a Swedish clinical-stage biotechnology company, and ITM Isotope Technologies Munich SE, a German radiopharmaceutical biotechnology company, recently announced the signing of a supply agreement. Under the agreement, ITM will supply no-carrier-added lutetium-177 (nca Lu-177) to Akiram to support the clinical development of its targeted antibody-radionuclide conjugate, 177Lu-AKIR001 (AKIR001). AKIR001 is Akiram's lead radiopharmaceutical candidate, currently being investigated in clinical studies for the treatment of CD44v6-expressing solid tumors. The candidate combines the therapeutic radioisotope nca Lu-177 with a proprietary antibody targeting CD44v6. CD...

2026-08-20

Automatic Radiation Environment Monitoring Station in Mianyang, Sichuan Put into Trial Operation, with Core Equipment and Systems Achieving Domestic Localization

Recently, the automatic radiation environment monitoring station located within the Nuclear Medical Health Industrial Park of the China (Mianyang) Science and Technology City was officially put into trial operation. As the first automatic radiation environment monitoring station in Sichuan Province to fully achieve domestic localization of core equipment and systems, it will provide radiation environment safety assurance for the development of the nuclear medical industry in the park through 24-hour uninterrupted automatic monitoring capabilities. At the automatic radiation environment monitoring station, operational data from equipment such as environmental γ dose rate monitors are updated in real time on monitoring screens. Compared with the previous approach that relied on manual on-site sampling and batch laboratory analysis, the automatic station enables continuous monitoring, reducing the time required to produce monitoring results from several days to the same day, thereby improving...

2026-08-20

Yonsei Cancer Hospital in South Korea Expands Heavy Ion Radiotherapy Indications, Three Systems Operating Simultaneously

Yonsei Cancer Hospital in South Korea recently announced that it has further expanded the indications for heavy ion radiotherapy to include head and neck cancer, sarcoma, and recurrent rectal cancer. Since becoming the first hospital in South Korea to perform heavy ion radiotherapy for prostate cancer in 2023, the hospital has gradually expanded its treatment scope to cover pancreatic cancer, liver cancer, lung cancer, and other cancer types. Medical staff, including Proton Therapy Center Director Kim Woong-sub (left), are preparing for proton therapy. (Photo provided by Yonsei University Medical Center) Meanwhile, the hospital's second rotating heavy ion radiotherapy system has been fully commissioned. This brings the hospital to a configuration of one fixed-beam system and two rotating systems operating simultaneously. The hospital...

2026-08-20

Canada Approves Bruce Power Hot Cell Facility Operations, Strengthening Lutetium-177 Medical Isotope Supply Chain

Bruce Power has recently received approval from the Canadian Nuclear Safety Commission to operate its on-site hot cell facility for target carrier removal (TCR) work, a critical step in the production process of the medical isotope lutetium-177 (Lu-177). Lu-177 is used in the treatment of prostate cancer and is increasingly applied in targeted therapies for precision medicine. Under the approval, Bruce Power can perform the relevant processing steps on site, further streamlining the isotope production process, reducing transportation requirements, while helping to enhance operational safety, lower emissions, and strengthen Ontario's capabilities in the global medical isotope supply chain. The hot cell facility was completed earlier this year...

2026-08-20

Russian enterprise develops borated polyethylene material for neutron radiation protection

A neutron radiation protection material developed by Russian company NPO Gelar has obtained relevant certification. The material, named Polikeramoplast-PB, is a borated polyethylene that resembles ordinary gray or black plastic sheets in appearance, but its protective performance derives from the combination of hydrogen and boron. According to reports, the hydrogen in the material effectively moderates fast neutrons, reducing the likelihood of subsequent secondary reactions, while the boron helps absorb moderated neutrons. In contrast, traditional heavy metal materials used for gamma-ray shielding are not suitable for standalone neutron protection, as heavy atomic nuclei have limited attenuation effects on neutrons. The material can be used in radiation therapy room protection systems and combined with lead...

2026-08-19

Norway's Thor Medical AlphaOne High-Purity Alpha Radioisotope Facility to Be Officially Inaugurated

Thor Medical ASA announced on August 19 that its AlphaOne production facility at the Herøya industrial park in Norway will be officially inaugurated on September 9, 2026, with Norwegian Prime Minister Jonas Gahr Støre attending the ceremony. According to reports, AlphaOne is Thor Medical's first industrial-scale production facility for high-purity α radioisotopes and the first of its kind globally. The facility is already in operation, primarily producing isotope products for next-generation targeted cancer therapies, supplying high-purity α emitters to the radiopharmaceutical industry. Thor Medical CEO Jasper Kurth stated that AlphaOn...

2026-08-19